Rhinitis, Allergic Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Single-center Clinical Trial of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis
The goal of this clinical trial is to learn about the clinical efficacy and safety of ganciclovir (GCV) capsules in the treatment of refractory moderate-to-severe allergic rhinitis. The main questions it aims to answer are: 1. Whether ganciclovir improve nasal symptoms and life quality in patients with refractory moderate-to-severe allergic rhinitis. 2. Whether ganciclovir is safe for the treatment of allergic rhinitis. Participants with refractory moderate-to-severe allergic rhinitis will be included in the trial based on the inclusion and exclusion criteria, and randomized into experimental and control groups. The two groups will be treated with blinded ganciclovir capsules or placebo for two weeks, with the background therapy of mometasone furoate aqueous nasal spray. A placebo is a look-alike capsule that contains no active drug. Nasal symptom scores, nasal secretions, blood samples and adverse events will be collected during the visits. Researchers will compare the experimental and control groups to see whether ganciclovir improve symptoms and is safe for the treatment of refractory moderate-to-severe allergic rhinitis.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | December 2025 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Aged between 18 and 65 years. 2. Diagnosed with moderate-to-severe perennial allergic rhinitis based on Chinese guideline for diagnosis and treatment of allergic rhinitis (2022, revision) with Allergic Rhinitis Control Test (ARCT) score <20. 3. Total Nasal Symptom Score (TNSS) =6 or at least two of the four subdomains(sneezing, rhinorrhea, nasal itching, and nasal obstruction) =2 at the time of both screening and randomization. And the improvement in TNSS was assessed as < 30% at randomization compared to screening. 4. The participant is allergic to dust mites or other perennial allergens 5. Voluntarily participate in the clinical trial and sign the informed consent. Exclusion Criteria: 1. Participants with hypersensitivity to ganciclovir capsules and its excipients. 2. Have symptoms of viral infection, fever and other systemic symptoms in the past 2 weeks. 3. Pregnant or lactating women and participants who have pregnancy plan during the study period. 4. Participants with severe neutropenia (absolute neutrophil count less than 0.5*10^9/L) or severe thrombocytopenia (platelet count less than 2.5*10^10/L). 5. Comorbidities such as upper and lower respiratory tract infections, history of acute or chronic sinusitis, dry rhinitis, atrophic rhinitis, severe deviated septum and asthma. 6. Participants with other severe heart, lung, liver and kidney disease. 7. Participants who had received any live or attenuated vaccine within 4 weeks prior to baseline or intended to receive live or attenuated vaccine (or BCG treatment) during the study period or within 4 weeks after the last administration of the investigational drug product. 8. Participants with a history of HIV infection or who test positive for HIV serology. 9. Participants currently infected or chronically infected with hepatitis B virus (HBV) or hepatitis C virus (HCV). 10. Participants with cirrhosis and/or chronic hepatitis. 11. Participants who have been diagnosed with active parasitic infections or are at high risk of developing such infections.? 12. Participants with a known or suspected history of immunosuppression, including a history of invasive opportunistic infections (e.g., histoplasmosis, listeriosis, coccidioidomycosis, pneumosporidiosis, aspergillosis). Or participants with what researchers believe to be unusually frequent, recurring, or prolonged infections. 13. Participants with a known history of malignancy within 5 years prior to screening. 14. Participants with severe co-morbidities that, in the opinion of the investigator, would adversely affect their participation in this study. 15. Participants with combined neurological or psychiatric disorders who are unable or reluctant to cooperate. 16. Participants with disabilities prescribed by law (blind, deaf, mute, mentally challenged, mentally handicapped, etc.). 17. Participants suspected or having a history of alcohol and drug abuse. 18. Other participants who have been involved in other clinical trials within 3 months before the screening. 19. The researchers consider it inappropriate to participate in this clinical trial. |
Country | Name | City | State |
---|---|---|---|
China | Wuhan Union Hospital | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Wuhan Union Hospital, China |
China,
Crumpacker CS. Ganciclovir. N Engl J Med. 1996 Sep 5;335(10):721-9. doi: 10.1056/NEJM199609053351007. No abstract available. — View Citation
Demoly P, Calderon MA, Casale T, Scadding G, Annesi-Maesano I, Braun JJ, Delaisi B, Haddad T, Malard O, Trebuchon F, Serrano E. Assessment of disease control in allergic rhinitis. Clin Transl Allergy. 2013 Feb 18;3(1):7. doi: 10.1186/2045-7022-3-7. — View Citation
Demoly P, Jankowski R, Chassany O, Bessah Y, Allaert FA. Validation of a self-questionnaire for assessing the control of allergic rhinitis. Clin Exp Allergy. 2011 Jun;41(6):860-8. doi: 10.1111/j.1365-2222.2011.03734.x. Epub 2011 Apr 25. — View Citation
Ding Z, Mathur V, Ho PP, James ML, Lucin KM, Hoehne A, Alabsi H, Gambhir SS, Steinman L, Luo J, Wyss-Coray T. Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation. J Exp Med. 2014 Feb 10;211(2):189-98. doi: 10.1084/jem.20120696. Epub 2014 Feb 3. — View Citation
Mathur V, Burai R, Vest RT, Bonanno LN, Lehallier B, Zardeneta ME, Mistry KN, Do D, Marsh SE, Abud EM, Blurton-Jones M, Li L, Lashuel HA, Wyss-Coray T. Activation of the STING-Dependent Type I Interferon Response Reduces Microglial Reactivity and Neuroinflammation. Neuron. 2017 Dec 20;96(6):1290-1302.e6. doi: 10.1016/j.neuron.2017.11.032. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of improvement in TNSS scores | After 2 weeks of medication, the investigator assessed the rate of change in the difference in TNSS from baseline. Calculated as (total post-treatment symptom score - total pre-treatment symptom score)/total pre-treatment symptom score × 100%. | From baseline to the end of treatment (2 weeks) | |
Secondary | Total effective rate | Participants with a >30% decrease in total nasal symptom scores (TNSS) after 2 weeks of treatment are considered effective. The percentage of participants effective on treatment will be assessed as total effective rate. | From baseline to the end of treatment (2 weeks) | |
Secondary | Rate and absolute value of change in TNSS and four subdomains. | TNSS assesses symptom severity in four subdomains consisting of sneezing, rhinorrhea, nasal itching, and nasal obstruction. Each subdomain is rated on a scale of 0 (no symptoms) to 3 (severe symptoms that are difficult to tolerate and interfere with daily activity). The overall TNSS score is the sum of all four symptoms resulting in a maximum score of 12. | From baseline to the end of treatment (2 weeks) | |
Secondary | Rate and absolute value of change in visual analogue scale (VAS) scores | The VAS ranges from 0 to 100. A score of 0 corresponds to no symptoms and 100 corresponds to the worst symptoms. | From baseline to the end of treatment (2 weeks) | |
Secondary | Rate and absolute value of change in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) | RQLQ is a validated QOL instrument consisting of 28 questions in seven domains (limited activity, sleep, practical problems, nasal symptoms, eye symptoms, emotional function, and non-nose/eye or other symptoms). Each domain is graded from zero (not impaired at all) to six (severely impaired), and the overall RQLQ is the mean score of all 28 responses | From baseline to the end of treatment (2 weeks) | |
Secondary | Change in mean TNSS during a 2-week administration period | Participants assess the TNSS score on a daily basis. TNSS assesses symptom severity in four subdomains consisting of sneezing, rhinorrhea, nasal itching, and nasal obstruction. Each subdomain is rated on a scale of 0 (no symptoms) to 3 (severe symptoms that are difficult to tolerate and interfere with daily activity). The overall TNSS score is the sum of all four symptoms resulting in a maximum score of 12. | During the 2-week administration period |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02424539 -
A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR)
|
Phase 4 | |
Completed |
NCT00770315 -
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)
|
Phase 3 | |
Completed |
NCT02486159 -
The Oligonucleotide Chip Analysis for Allergic Rhinitis Treatment in Herbal Plaster and Acupuncture
|
N/A | |
Completed |
NCT00771160 -
MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED)
|
Phase 3 | |
Completed |
NCT00834119 -
Assessment of Intranasal Steroids in Allergic Rhinitis When Used Alone or in Combination With an Oral Antihistamine (Study P03270)
|
Phase 4 | |
Recruiting |
NCT04435990 -
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
|
Phase 3 | |
Recruiting |
NCT05177744 -
Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
|
||
Recruiting |
NCT05621356 -
Monitoring Allergen Immunotherapy in Allergic Rhinitis
|
||
Not yet recruiting |
NCT06330974 -
Allergy, Asthma, and Atopic Eczema in Finland
|
||
Completed |
NCT03758456 -
HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human
|
Phase 1 | |
Completed |
NCT04645979 -
A Study to Learn What Participants Think of Treatment With Betamethasone Plus Loratadine to Treat Their Acute Allergic Rhinitis, Also Known as Hay Fever in Mexico
|
||
Completed |
NCT05122143 -
Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers
|
N/A | |
Completed |
NCT05901532 -
Nasal Irrigation With Chinese Herbal Medicine as an Adjunctive Treatment in Allergic Rhinitis
|
Phase 2 | |
Terminated |
NCT02722083 -
Exploratory Study for Allergy Relief Onset
|
Phase 2 | |
Recruiting |
NCT05656482 -
Ability of a Cat Food to Reduce Respiratory Symptoms in Cat Allergic Patients
|
||
Recruiting |
NCT04898283 -
Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
|
Phase 3 | |
Recruiting |
NCT05922176 -
Biomarker Screening for Immunotherapy Response Evaluation Using Microneedle Patch in Patients With Allergic Rhinitis
|
||
Completed |
NCT02679105 -
Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy
|
Phase 2/Phase 3 | |
Completed |
NCT01104012 -
Validation of Proteomic Analyses for Allergic Asthma and Rhinitis
|
N/A | |
Completed |
NCT03375775 -
Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children
|
N/A |